- Large treatment-naïve population
- High disease population load
- The clinical activity grew by over 40% in 2018 on the back of regulatory pathway improvements
- About 1,800 investigators have participated on a minimum of 5 studies
India is the world’s second most populated country with 1.3 billion people. Over the past decade, India has implemented an internationally recognized regulatory system making it increasingly attractive for the clinical trial sector.
India’s healthcare system is developing rapidly and expanding to cover an increasing percentage of the population. Growth in the pharmaceutical industry is being driven by epidemiological factors, increasing affordability and enhanced accessibility.
India has high levels of wage inequity, so while rural areas continue to struggle with infectious diseases and sanitation, wealthy urban areas are seeing an increase in developed nations’ lifestyle diseases including diabetes and heart disease.
Novotech has established strong clinical teams in India with deep local knowledge to deliver quality CRO services to biotechnology companies. In addition, it has partnered with key specialist hospital and research facilities giving Novotech clients direct access to the most active and reputable KOLs, PIs and sites to facilitate study start-up and patient recruitment.
Novotech Clinical Research India Private Limited
Unit No 302, Embassy Square, 148 Infantry Road, Bangalore 560001